8-K: Foghorn Therapeutics and Lilly Advance FHD-909 into Clinical Development for BRG1 Mutated Lung Cancer

Foghorn Therapeutics announces that Eli Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development, with an IND filing planned for the second quarter of 2024.

Summary

• Foghorn Therapeutics is advancing its pipeline with a focus on chromatin biology, which is implicated in a large percentage of tumors.
• The company has a strategic collaboration with Eli Lilly, including a 50/50 U.S. economic split on two lead programs.
• Foghorn has $259.9 million in cash and equivalents as of September 30, 2023, providing a financial runway into the first half of 2026.
• A key development is the selection of FHD-909, a BRM selective inhibitor, by Lilly for clinical development, targeting BRG1 mutated non-small cell lung cancer.
• Lilly plans to file an Investigational New Drug (IND) application for FHD-909 in the second quarter of 2024.
• Foghorn is also anticipating data from the Phase 1 study of FHD-286 in combination with decitabine in the second half of 2024.
• The company is advancing preclinical assets, including a BRM selective degrader, CBP, EP300, and ARID1B, towards IND filings.
• Foghorn's Gene Traffic Control platform is used to identify and validate drug targets within the chromatin regulatory system.

Sentiment

Score: 8

Explanation: The document is very positive due to the advancement of FHD-909 into clinical development, the strong collaboration with Lilly, and the company's solid financial position. The company has a clear strategy and a broad pipeline, which are all positive indicators.

Positives

• The collaboration with Lilly validates Foghorn's technology and provides significant financial and development support.
• FHD-909's selection for clinical development is a major milestone, indicating its potential as a treatment for BRG1 mutated cancers.
• The company's strong cash position provides a long runway for continued research and development.
• FHD-286 has shown promising results in AML, including differentiation and potential for combination therapies.
• Foghorn's Gene Traffic Control platform is a unique and scalable approach to drug discovery.
• The company has a broad pipeline with multiple targets and modalities, increasing the potential for successful drug development.

Negatives

• The company is still in the early stages of clinical development, and there are risks associated with clinical trials.
• The company is reliant on CDMOs and CROs for manufacturing and research needs.
• There are inherent uncertainties and risks associated with forward-looking statements, and actual results may differ materially.
• The company faces competition from other companies in the biotechnology and pharmaceutical industries.

Risks

• Clinical trials may not be successful, and product candidates may not receive regulatory approval.
• The company's research and development programs may be delayed or unsuccessful.
• The company may not be able to identify and enter into future license agreements and collaborations.
• The company may not be able to protect its intellectual property rights.
• The company may need to raise additional capital in the future.
• Macroeconomic and geopolitical circumstances could impact the company's business operations.

Future Outlook

The company anticipates data from the Phase 1 study of FHD-286 in combination with decitabine in H2 2024 and plans to advance preclinical assets towards IND filings. Lilly plans to file an IND for FHD-909 in Q2 2024.

Management Comments

• Selective BRM inhibition has been a sought-after objective in cancer research for many years.
• Selective blocking of BRM activity is considered a promising strategy for causing tumor cell death while sparing healthy cells.

Industry Context

This announcement highlights the growing interest in targeting chromatin biology for cancer treatment. The collaboration with Lilly underscores the potential of Foghorn's approach and its position as a leader in this area. The focus on BRM inhibition aligns with the industry's pursuit of precision medicines that target specific genetic dependencies in tumors.

Comparison to Industry Standards

• Foghorn's approach to targeting chromatin biology is unique compared to traditional cancer therapies that focus on other pathways.
• The collaboration with Lilly is a significant validation of Foghorn's technology, as Lilly is a major player in the pharmaceutical industry.
• The 50/50 co-development and co-commercialization agreement with Lilly is a favorable arrangement for Foghorn, allowing them to share costs and profits.
• The focus on BRM inhibition is a novel approach, as most current therapies do not target this specific mechanism.
• The company's pipeline includes multiple targets and modalities, which is a broader approach than many other companies in the space.
• The company's cash position of $259.9 million is relatively strong for a company at this stage of development, providing a runway into H1 2026.

Stakeholder Impact

• Shareholders will likely view the news positively due to the advancement of the pipeline and the collaboration with Lilly.
• Employees may be motivated by the progress of the company's research and development efforts.
• Patients with BRG1 mutated cancers may benefit from the development of FHD-909.
• The collaboration with Lilly could lead to increased revenue and growth for the company.

Next Steps

• Lilly plans to file an IND for FHD-909 in the second quarter of 2024.
• Foghorn anticipates data from the Phase 1 study of FHD-286 in combination with decitabine in the second half of 2024.
• The company will continue to advance preclinical assets towards IND filings.
• The companies plan to present preclinical data at upcoming scientific conferences.

Key Dates

Keywords

BRM inhibitor, FHD-909, BRG1, chromatin biology, cancer, oncology, Lilly, Gene Traffic Control, AML, FHD-286, protein degrader, precision medicine